Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

This phase I study tests a new experimental cell therapy made from umbilical cord-derived natural killer (NK) cells that have been engineered to better resist the tumor's defenses. It is designed for patients 12 and older with recurrent high-grade brain cancer (glioblastoma) that has come back after previous treatment. **You may be eligible if...** - You are 12 years or older with confirmed recurrent high-grade glioblastoma or related brain tumor - You have previously received radiation and temozolomide chemotherapy - Your general performance status (Karnofsky/Lansky score) is above 70 - Your blood counts, liver, and kidney function are adequate - You are at least 12 weeks out from radiation (unless your cancer progressed early) - You are willing to use contraception during and for 3 months after treatment **You may NOT be eligible if...** - You previously received bevacizumab (Avastin) or Gliadel wafers - You have a known immunodeficiency or are on immunosuppressive medications - You have active HIV, hepatitis B, or hepatitis C - You have had a prior organ or stem cell transplant - You are pregnant or breastfeeding - Your tumor is in the brainstem or spine, or larger than 5 cm - You have active autoimmune disease requiring systemic treatment Talk to your doctor to see if this trial is right for you.